The Company treated the first patient in the pivotal Phase 3 OVATION 3 Study in July 2025 and is working with trial investigators to expand clinical sites and accelerate enrollment. Four sites have ...

Genenta Science S.p.A. stock surged after ANEMOCYTE partnership. Discover temferon's cancer trial updates and what’s next.

Genenta Science (NasdaqCM:GNTA) recently drew widespread attention after announcing an expanded partnership with Anemocyte, centered on advancing off-the-shelf lentiviral vector Plasmid DNA technology ...

Genenta & Anemocyte ink partnership to advance off-the-shelf LVV Plasmid DNA production: Milan Monday, October 27, 2025, 14:00 Hrs [IST] Genenta Science, a pioneer company in immu ...

Genenta Science shares surged by more than double Friday after the company said it has partnered with Anemocyte to collaborate on its plasmid DNA technology platform. The stock was briefly halted from ...

Genenta Science shares surged 300% in premarket trading on Friday after announcing an expanded collaboration with ANEMOCYTE.

Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today ...

The partnership leverages Genenta's robust and well-tested LVV Plasmid DNA technology, a platform developed from the foundational research of Professor Luigi Naldini, co-founder of Genenta. This ...

If you're interested in broad exposure to the Technology - Broad segment of the equity market, look no further than the Vanguard Information Technology ETF (VGT), a passively managed exchange traded ...

ROCKVILLE, Md., Oct. 8, 2025 /PRNewswire/ -- Ascend Advanced Therapies (Ascend), a gene-to-GMP development partner, today announced that its European patent EP3722434, protecting EpyQ®, the company's ...